A Study of Participants With Advanced Prostate Cancer in Canada

Official Title

A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada


The purpose of this study is to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management.

Trial Description

Primary Outcome:

  • Time to Prostate Specific Antigen (PSA) Progression
  • Time to Radiographic Evidence of Disease Progression
  • Time to Skeletal-Related Events
  • Time to Death
  • Number of Participants with Different Primary Causes of Death
  • Time to Progression from mCSPC to mCRPC in Participants with mCSPC
  • Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC
  • Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC
  • PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC
  • PSA Doubling Time (PSAdt) at the Detection of Castration Resistance in Participants with mCRPC
  • Time to Initiation of Subsequent Prostate Cancer Treatment
  • Duration of Each Therapy
  • Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment
  • Time to Treatment Initiation
  • Time to Dose Modification
  • Number of Participants who Switch the Treatment
  • Number of Participants who Discontinued the Treatment
  • Most Common Sequences for Lines of Therapy in Participants with mCRPC
  • Number of Participants Retreated with Docetaxel in Participants with mCRPC
  • Percentage of Participant with Radiographic Imaging Modality
  • Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer
  • Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer
  • Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer
  • Charlson Comorbidity Index Score

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society